慢性丙型肝炎病毒(chronic hepatitis C，HCV)感染的治疗在过去的几年取得了长足的进步。但某些特定人群中：如肾功能不全或肝硬化患者的HCV 治疗仍然是一个难题。慢性肾脏病患者HCV感染率较普通人群高，发病率和死亡率也更高。因此，感染HCV 的肾脏病患者应及时接受抗病毒治疗。直接抗病毒药物(Directly-acting antiviral agent，DAA)出现使合并HCV 感染的慢性肾脏病患者治疗取得突破性进展。但慢性肾脏病患者最佳DAA 治疗方案仍有争议，本文就合并HCV 感染的慢性肾脏病患者抗病毒治疗作一综述。

The treatment of chronic hepatitis C virus (HCV) infection has been improved significantly in the past few years. However, there still remain therapeutic difficulties in this area for several specific populations such as renal insufficiency and cirrhosis patients. The incidence of HCV infection in chronic kidney
disease (CKD) patients is higher than that in the average population, resulting in increased morbidity and mortality in CKD patients. Therefore, CKD patients with HCV infection should be treated with antiviral therapy in time. The emergence of directly-acting antiviral drugs (DAAs) has made a breakthrough for the infection in CKD patients. However, the optimal DAAs regimen for CKD patients is yet controversial. This review focuses on the progress of anti-HCV therapy for CKD patients in the past few years.